Welcome to our dedicated page for United Therapeutics SEC filings (Ticker: UTHR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
United Therapeutics Corporation filings document an operating biotechnology company with Nasdaq-listed common stock and a public benefit corporation structure. Recent 8-K reports cover quarterly and annual operating results, business updates, clinical-study announcements for Tyvaso and ralinepag, and capital actions such as share repurchase programs and accelerated share repurchase agreements.
Proxy materials describe board elections, director changes, executive compensation, shareholder voting matters and governance practices. The company’s formal disclosures also address its treprostinil-centered pulmonary arterial hypertension business, development programs in pulmonary and transplant-related medicine, and common-stock capital structure.
Paul Mahon has filed a notice of proposed sale of 8,300 shares of United Therapeutics common stock, with an aggregate market value of 4,010,939.31. The shares are to be sold through Morgan Stanley Smith Barney LLC on or about 02/05/2026 on the NASDAQ.
The 8,300 shares to be sold were acquired on 02/05/2026 via a stock option exercise paid in cash. The filing also lists prior sales over the past three months, including four 11,000-share sales in November and December 2025 and two 8,300-share sales in January 2026, with gross proceeds ranging from 3,900,121.86 to 5,644,953.60. Shares outstanding are reported as 43,056,599.
United Therapeutics director Malcolm Jan reported a small planned share sale. On 02/03/2026, he sold 50 shares of United Therapeutics common stock at $474.23 per share in an open-market transaction coded "S." The sale was made under a pre-arranged Rule 10b5-1 trading plan that he entered into on September 11, 2025.
After this transaction, Jan beneficially owned 270 shares of United Therapeutics common stock, held in direct ownership form.
United Therapeutics president and COO Michael Benkowitz reported pre‑planned option exercises and share sales through family trusts. On February 2, 2026, trusts associated with him exercised 14,625 stock options at $117.76 and 7,875 options at $146.03, then sold the resulting common shares at $470.9524 per share under a Rule 10b5‑1 trading plan entered on June 3, 2025. After these indirect transactions, he continued to hold 2,648 shares of common stock directly, while retaining beneficial ownership and investment/voting power over the trust holdings as described in the filing.
An insider of UTHR has filed a Rule 144 notice to sell 50 shares of common stock through Morgan Stanley Smith Barney LLC on the NASDAQ. The filing lists an aggregate market value of $23,711.50 for these shares and shows 43,056,599 shares outstanding.
The shares to be sold were acquired as restricted stock from the issuer on 06/26/2025. Over the past three months, the same seller reported four prior sales of 50 shares each, with gross proceeds of $25,606.00, $24,149.00, $23,049.00, and $24,750.50.
A Form 144 notice has been filed for the proposed sale of 90000 shares of common stock through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of 42254100.00. The issuer reports 43056599 shares outstanding at the time of the notice.
The 90000 shares were acquired on 02/02/2026 via a cash exercise of stock options from the issuer. The filing also lists multiple prior Rule 10b5-1 common stock sales for Michael Benkowitz over the past three months, each with specified share amounts and gross proceeds.
United Therapeutics Corporation’s President and COO Michael Benkowitz reported multiple pre-planned insider transactions involving company stock held in trusts associated with him. On January 20, 2026, a trust exercised 7,875 stock options at an exercise price of $146.03 per share and sold the resulting common shares in a series of trades at weighted-average prices ranging from about $456.8652 to $470.755, reducing that trust’s common stock position to zero.
On January 26, 2026, a trust where he and his spouse are co‑trustees exercised 14,625 stock options at an exercise price of $117.76 per share and sold 14,625 common shares at a weighted-average price of $471.9081. A second trust exercised 7,875 stock options at $146.03 per share and sold 7,875 common shares at $471.9081. The filing notes these option exercises and share sales were made under a Rule 10b5‑1 trading plan entered into on June 3, 2025. Following these transactions, trusts associated with Benkowitz continued to hold stock options, and he also held 2,648 shares of common stock directly.
United Therapeutics Corp’s president and COO Michael Benkowitz reported an automatic transaction by a trust associated with him. On January 20, 2026, the trust exercised stock options for 14,625 shares of common stock at an exercise price of $146.03 per share and received 14,625 shares.
That same day, the trust sold all 14,625 shares in multiple trades at weighted‑average prices between $456.34 and $470.70, under a Rule 10b5‑1 trading plan adopted on June 3, 2025. After these sales, the trust held 0 shares of common stock, while Benkowitz held 2,648 shares directly and 67,875 stock options indirectly through the trust, over which he and his spouse share investment and voting power.
United Therapeutics Corporation disclosed that new director Kevin Tracey received a grant of restricted stock units on January 21, 2026. The award covers 1,220 restricted stock units, each representing the right to receive one share of United Therapeutics common stock after vesting. The units were granted at a price of $0.00 in connection with his appointment to the Board of Directors under the company’s Non-Employee Director Compensation Program.
The award becomes fully vested on the one-year anniversary of the grant date, January 21, 2027. Following this grant, Tracey beneficially owns 1,220 derivative securities in the form of restricted stock units, held directly.
United Therapeutics Corp director Tracey Kevin filed an initial ownership report on Form 3. The filing states that no United Therapeutics securities are beneficially owned. This means the reporting person, who is a director of the company, is formally disclosing that they do not currently hold any direct or indirect ownership in the company’s stock or derivative securities under the applicable reporting rules.
United Therapeutics Corporation reported governance updates. On January 21, 2026, the Board of Directors increased its size to 13 members and appointed Kevin J. Tracey, M.D. as a new director, based on the recommendation of the Nominating and Governance Committee. He will initially serve without a committee assignment, and the company states there are no related-party transactions involving him above the disclosure threshold.
In connection with his appointment, Dr. Tracey received 1,220 restricted stock units under the company’s Amended and Restated 2015 Stock Incentive Plan, consistent with its standard non-employee director compensation program, and entered into the company’s standard indemnification agreement for directors and executive officers. The Board also approved and put into effect the Eleventh Amended and Restated Bylaws, which restate and amend the prior bylaws and include various technical conforming changes. A press release announcing Dr. Tracey’s appointment was furnished as an exhibit.